Introduction to Drug Metabolism
1. Definition
Drug metabolism, or biotransformation, is the chemical modification of a drug, mainly through enzymatic reactions, into one or more metabolites. These metabolites may be active, inactive or toxic.
2. Purpose
Metabolism generally decreases a drug’s lipid solubility and increases its polarity, facilitating its excretion from the body, for example in urine or bile.
Drug metabolism usually promotes elimination by making substances more polar and less lipid-soluble.
3. Sites of metabolism
The liver is the main site of drug metabolism because it has a substantial blood supply of approximately 1.5 L/min and extensive enzyme equipment. Other organs can also contribute, including the intestine, lungs and kidneys.
Sites of Drug Metabolism
1. Main sites of drug metabolism
The liver is the major site of drug metabolism. Metabolism also occurs in other tissues, including the skin.
At the cellular level, drug-metabolising enzymes are mainly located in:
| Cellular location | Enzyme group |
|---|---|
| Smooth endoplasmic reticulum | Microsomal enzymes |
| Cytoplasm | Cytosolic enzymes |
| Mitochondria | Monoamine oxidase (MAO) |
2. Consequences of drug metabolism
Metabolism can alter a drug’s activity in several ways:
| Consequence | Example |
|---|---|
| Inactivation | 6-Mercaptopurine, an antineoplastic drug, is inactivated by hydroxylation to thiouric acid; the reaction is catalysed by xanthine oxidase (XO). |
| Activation | Mycophenolate mofetil is a prodrug converted by desesterification to mycophenolic acid, an immunosuppressant. |
| Potentiation | Imipramine, an antidepressant, is demethylated to desipramine, which is also an antidepressant. |
| Formation of toxic metabolites | Paracetamol can undergo oxidation to form a reactive, toxic metabolite. |
Consequences of Drug Metabolism
1. Phase I: functionalisation
Phase I reactions modify a drug or add a functional group, such as hydroxyl (), amine () or carboxyl (). They can produce a more polar metabolite.
| Reaction | Key point |
|---|---|
| Oxidation | Mainly catalysed by cytochrome P450 enzymes (CYPs). |
| Reduction | Adds or modifies functional groups. |
| Hydrolysis | Cleaves chemical bonds using water. |
Phase I is not compulsory: some drugs proceed directly to Phase II.
2. Phase II: conjugation
Phase II enzymes, mainly transferases, attach an endogenous molecule or group to the drug or its Phase I metabolite. Conjugation generally increases water solubility, facilitating elimination.
| Conjugation reaction | Group transferred | Enzyme | Example |
|---|---|---|---|
| Glucuronidation | Glucuronic acid | UDP-glucuronyl transferases | Morphine, paracetamol |
| Sulfation | Sulfate | Sulfotransferase | Methyldopa, paracetamol |
| Glycine conjugation | Glycine | Glycine N-acyltransferase | Nicotinic acid |
| Acetylation | Acetyl | N-acetyltransferase | Isoniazid |
| Alkylation | Methyl | Methyltransferase | — |
The functional groups that can undergo conjugation include , , and ; alkylation can also act on electrophiles.
3. Elimination and consequences
More hydrophilic metabolites can be eliminated through the kidneys or into the intestine and excreted in faeces. However, intestinal deconjugation may regenerate the drug or metabolite, allowing reabsorption.
Metabolism can also generate reactive products that cause cellular stress or form protein adducts.
Phases of Drug Metabolism
1. Phases of drug metabolism
Drug metabolism is commonly organised into three phases. Some drugs undergo several metabolic pathways.
| Phase | Main process | Outcome |
|---|---|---|
| Phase I | Functionalisation, commonly through oxidation | Introduces or exposes a functional group |
| Phase II | Conjugation | Links the drug or a Phase I metabolite to an endogenous molecule |
| Phase III | Further processing and elimination | Supports transport and removal of metabolites |
Glutathione conjugation is one example of Phase II metabolism: glutathione transferase catalyses conjugation, which can lead to formation of mercapturic acid. Paracetamol may also form protein adducts, associated with oxidative stress.
2. Factors affecting metabolic variability
Differences in metabolism can lead to reduced efficacy, a prolonged therapeutic effect, or increased toxicity.
a) Physiological factors: age and pregnancy
Metabolic activity varies with age: it is immature in neonates and generally lower in older adults. During pregnancy, progesterone can increase microsomal activity.
b) Genetic polymorphism
The activity of some metabolic pathways is genetically controlled, so metabolic efficiency varies between individuals. Mutations affecting enzyme synthesis can produce different alleles and therefore polymorphism in the phenotype.
| Example | Variation |
|---|---|
| Acetylation | Slow or rapid acetylators |
| Cytochrome P450 enzymes | CYP2D6, CYP2C9 and CYP2C19 |
c) Pathological factors
Pathological factors are also listed as a category affecting metabolic variability.
Factors Affecting Metabolic Variability
1. Drug combinations and metabolic variability
Drug combinations can alter plasma drug concentrations by changing the activity of drug-metabolising enzymes, particularly CYP isoenzymes. Concentrations may fall below the effective range, remain therapeutic, or rise into the toxic range.
| Process | Definition |
|---|---|
| Enzyme induction | Increased CYP isoenzyme activity after exposure to an inducing substance. |
| Enzyme inhibition | Decreased CYP isoenzyme activity after exposure to an inhibitory substance. |
2. Enzyme induction
Induction increases the synthesis of hepatic microsomal enzymes (CYP450). It develops gradually, reaches its maximum effect after 10–15 days, and may persist for several days after the inducer is stopped.
Examples of inducers include rifampicin, phenobarbital, carbamazepine and phenytoin.
Induction can have different consequences depending on the metabolites formed:
| Metabolic consequence | Possible effect |
|---|---|
| Increased formation of inactive metabolites | Reduced or lost drug activity and shorter residence time in the body. |
| Increased formation of active metabolites | Increased therapeutic effect. |
| Formation of toxic metabolites | Increased toxicity. |
Clinical example: Phenobarbital can induce metabolism of oral contraceptives, reducing their effectiveness and increasing the risk of pregnancy.
Quantification of Drug Metabolism
1. Quantifying drug metabolism
Drug metabolism can be quantified by measuring how quickly a drug is converted into metabolites. The key measure is clearance, the volume of plasma from which drug is completely removed per unit time.
Enzyme inhibition can change this rate and therefore alter drug exposure:
| Effect of inhibition | Consequence | Example |
|---|---|---|
| Slower formation of inactive metabolites | Prolonged drug effect and increased toxicity risk | Atorvastatin with grapefruit juice: risk of rhabdomyolysis |
| Reduced formation of active metabolites | Reduced therapeutic effect or ineffectiveness | Levodopa with benserazide, a peripheral dopa-decarboxylase inhibitor; this allows lower doses and reduces peripheral dopamine-related effects such as nausea and hypertension |
Inhibition of metabolism may either increase toxicity by slowing drug inactivation or reduce efficacy by preventing formation of an active metabolite.
Conclusion
1. Drug clearance and extraction
Clearance (), expressed in mL/min, is the volume of blood completely cleared of a substance per unit time. It includes both biotransformation and excretion. An organ’s clearance describes its capacity to remove a drug from blood per unit time.
The extraction ratio () is the fraction of blood flowing through an organ that is completely cleared of the drug.
| Extraction category | Extraction ratio |
|---|---|
| Low | |
| Intermediate | |
| High |
2. Key conclusions
Biotransformation is a key component of drug pharmacokinetics. Phase I and Phase II reactions are complementary mechanisms that promote drug elimination. Physiological or pathological changes that affect the expression or activity of biotransformation enzymes can alter drug pharmacokinetics and may require dose adjustment.
Changes in drug-metabolising enzyme activity can alter pharmacokinetics and necessitate dose adjustment.